公开(公告)号：US20220152026A1

公开(公告)日：2022-05-19

申请号：US17430190

申请日：2020-02-10

Applicant: NOVARTIS AG

Inventor： Saskia Maria Brachmann ,  Danilo Maddalo ,  Anirudh Cadapa Prahallad

IPC: A61K31/517 ,  A61K31/497 ,  A61P35/00

Abstract: The present invention relates to a pharmaceutical combination comprising TNO155 and a KRASG12C inhibitor; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in a SHP2 inhibitor combined with KRASG12C inhibition is beneficial in, for example, the treatment of cancers.

公开(公告)号：US20180325883A1

公开(公告)日：2018-11-15

申请号：US16033764

申请日：2018-07-12

Applicant: Novartis AG

Inventor： Saskia Maria Brachmann ,  Christine Fritsch ,  Sauveur-Michel Maira ,  Christian Schnell ,  Carlos Garcia-Echeverria

IPC: A61K31/4439 ,  A61K39/395 ,  C07K16/32 ,  A61K31/517 ,  A61K45/06 ,  A61K39/00

CPC classification number: A61K31/4439 ,  A61K31/517 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2300/00 ,  C07K16/32 ,  C07K2317/24

Abstract: The use of compounds of formula (I) in the treatment of Epidermal Growth Factor Receptor (EGFR) dependent diseases or diseases that have acquired resistance to agents that target EGFR family members, use of said compounds for the manufacture of pharmaceutical compositions for the treatment of said diseases, combinations of said compounds with EGFR modulators for said use, methods of treating said diseases with said compounds and pharmaceutical preparations for the treatment of said diseases comprising said compounds alone or in combination, especially with an EGFR modulator.